Sobi’s CEO divests a portion of shares

Swedish Orphan Biovitrum AB’s (publ) (Sobi™) CEO Geoffrey McDonough has divested 300,000 of the shares he holds in the company. The sale was made for personal financial reasons. After the transaction, the CEO will hold a total of 347,948 shares in the company.


About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm.

For more information please contact

Media   relations Investor   relations
Charlotte   af Klercker, Sr Communications Manager Jörgen   Winroth, Vice President, Head of Investor Relations
T:   +46-707-297 327 T:   +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00



Documents & Links